# Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

> **NCT01959243** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 507 (actual)

## Conditions studied

- Hyperemia

## Interventions

- **DRUG:** Brimonidine Tartrate
- **DRUG:** Vehicle
- **DRUG:** Sodium Fluorescein
- **DRUG:** Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

## Key facts

- **NCT ID:** NCT01959243
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-22
- **Primary completion:** 2014-04-23
- **Final completion:** 2014-06-23
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2019-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959243, "Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01959243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*